NHS Dumfries and Galloway, Epilepsy Scotland, UCB Pharma and GlaxoSmithKline UK Limited joint working agreement
NHS Dumfries and Galloway, Epilepsy Scotland, UCB Pharma and GlaxoSmithKline UK Limited are working together to evaluate and subsequently improve services for People with Epilepsy in Dumfries and Galloway Health Board. The purpose of this project is to create an Epilepsy Patient Pathway in Dumfries & Galloway Health Board to improve and develop services in D&G for people with epilepsy to achieve Better quality care provided by well-educated and well-trained Healthcare professionals.
Within the project the key objectives are:
- To identify and improve the current epilepsy pathway and services, in line with the six key dimensions of quality for patient care1, (person-centred, safe, effective, efficient, equitable and timely)
- Establish the training needs required in primary care, secondary/acute care and Learning Disability (LD) services and to deliver training work in these three areas, together with provision of a GP annual review toolkit.
- To write up the outcomes of the Joint Working (JW) project for internal and external dissemination outcomes and to communicate key findings at Holyrood reception.
The benefits of the project:
- Patients will receive personalised care by HealthCare Professionals (HCPs) who have been trained in the management of epilepsy enabling them to receive access to appropriate treatment for their condition in accordance with national guidelines
- Patients may feel more valued and have less seizures by receiving optimum treatment Patients will receive care at locations nearer to their homes
- Patients will benefit from a smoother and more efficient pathway between primary and secondary care
- Patients and their carers will receive information, materials and improved support systems to enable them to better self manage and increased confidence with their condition
- Patients and/or their appropriate family members will have an opportunity to influence the design of an improved epilepsy service
- Meeting the requirements as set out in the SIGN Guidelines, heat targets and HIS standards. Seen as role model in Epilepsy care – demonstrate willingness to co-operate to benefit of patient
- Up skilled existing HCPs providing improved care across the epilepsy pathway ensuring that the patient is seen by the appropriate HCP
- Removal of variation in the service
- Support systems and information materials to enable staff to provide improved care and education for people diagnosed with epilepsy
- Improved patient journey through a service pathway increasing from first seizure to treatment plan and subsequent patient support
- Improving condition management through a provision of an epilepsy service linking primary and secondary care and staff competency will help to reduce the number of unplanned admissions and length of hospital stays.
UCB/GSK and Epilepsy Scotland
- Improve relationships and demonstrate the value of joint working with NHS Scotland, the third sector and the pharmaceutical industry
- Seen as a credible partner in establishing a model of pathway redesign and training that can be replicated in other areas gaining recognition at a political level
- This project will provide an opportunity for UCB, GSK, Epilepsy Scotland and NHS D&G to share best practice of JW in both internal and external publications, including but not limited to journal articles, conference abstracts, posters and presentations
- The Scottish Pathways Association (HIS) plan to showcase at the European Pathways Conference – Glasgow 2013
- Provide a platform for other JW projects in other disease areas in NHS D&G
- Increased opportunity for appropriate use of medicines, including GSK’s and UCB’s medicines, due to increase in patients and service
1. As identified by the Institute of Medicine and promoted by the Scottish Government in the Healthcare Quality Strategy for Scotland (Accessed 8th March 2013)
For further information please contact:
GSK UK Customer Contact Centre: +44 (0)800 221 441
UK/EPI/0025c/12(1) Archived 2017.